An exploratory, prospective, open ‐label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts

ConclusionIngenol mebutate gel was associated with a high number of AEs and withdrawals due to painful local and adjacent skin reactions. Furthermore, it showed promising efficacy in reducing AGW despite a difficult‐to‐treat population. Optimisation of the formulation is warranted to improve the safety profile of the treatment.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - October 10, 2017 Category: Dermatology Authors: H K Larsen, C A Banzhaf, S F Thomsen, M Gormsen, R E Schopf, M Haedersdal Tags: Original Article Source Type: research